Photocure ASA

Earnings Release • Mar 14, 2016

Photocure ASA Hexvix® data presented during the European Association of Urology congress

Photocure ASA Hexvix® data presented during the European Association of Urology congress

Hexvix real world evidence show improved recurrence free survival and health

care savings

Oslo, Norway, 14 March 2016: Photocure ASA (OSE: PHO), a specialty

pharmaceutical company focused on photodynamic technologies in dermatology and

cancer, is pleased to announce presentations  by urology researchers on Hexvix

during the European Association of Urology (EAU) annual meeting held in Munich,

Germany 11-15 March 2016.  The EAU is one of the largest International meetings

in urology, showcasing the latest and most relevant knowledge with more than

12,000 urologists and exhibitors from over 100 countries.  Hexvix is a

photosensitizing agent taken up selectively by the tumor cells in the bladder

that when exposed to blue light during a cystoscopic procedure results in a

bright pink fluorescence of the suspicious tissue.  Using Hexvix as an adjunct

to standard white light cystoscopy enables the urologist to better detect and

remove lesions, leading to a reduced risk of recurrence.

Dr. Kjetil Hestdal, President  & CEO of Photocure ASA comments: "We are

delighted to see the expanding body of evidence supporting Hexvix and its role

in the detection and management of bladder cancer.  Real world data now

demonstrates the clinical and health economic benefits of Hexvix in a day-to-day

clinic setting supporting its widespread use. As more urologists are exposed to

the continued flow of data with Hexvix, more patients will have access to its

substantive benefits."

The Hexvix evidence from theory with its unique mode of action, randomized

clinical trials, and real world evidence were presented by Professor Dr.

Maximillian Burger, Chair of Urology of the University of Regensburg during a

symposium "Moving Forward in Urological Cancers" sponsored by Ipsen Uro-

oncology, strategic commercialization partner for Hexvix in Europe, excluding

the Nordic region.

Burger highlighted that bladder cancer is often under recognized and

undertreated.  Despite the large majority of the audience voting that they

follow the guidelines he stated that there is still room for improvement.  He

concluded that "Hexvix has been proven to offer significant benefits in the

detection and reduction in recurrence rates and emerging real world evidence now

confirms these findings, and even indicates better patient outcomes- especially

in high risk non-muscle invasive bladder cancer (NMIBC) patients, where it

matters most.  The strong real world data can give us even more confidence

managing patients in our daily clinical practice.  It improves recurrence free

survival and there are significant savings to the health care system as every

third follow up TURB can be avoided."

Hexvix is recommended for use in the diagnosis and management of NMIBC patients

in the EAU guidelines, NICE guidelines as well as a number of country specific

guidelines across Europe. The EAU guidelines for the management of non-muscle

invasive bladder cancer (NMIBC) have been developed after thorough assessment of

all clinical, safety and outcomes evidence to provide recommendations on the

best practice for managing these patients, from diagnosis through treatment.

However, there is currently considerable variability across Europe with

adherence to EAU guidelines, as reported in a poster presentation by Dr. E. N.

Xylinas, Cochin Hospital, Paris Descartes University. "Improved adherence to the

EAU guidelines on the management of patients with NMIBC would ensure all

patients across Europe have access and may benefit from the optimal methods for

detecting and managing the disease like Hexvix Blue-Light cystoscopy" concludes

Dr. Xylinas.

For further information, please contact:

Kjetil Hestdal

President and CEO

Photocure ASA

Tel. +47 913 19 535

KH@photocure.com

About Photocure ASA

Photocure ASA, headquartered in Oslo, Norway, is a specialty pharmaceutical

company and world leader in photodynamic technology.  Based on our unique

propriety Photocure Technology® platform, Photocure develops and commercializes

highly selective and effective solutions in disease areas with high unmet

medical needs such as bladder cancer, HPV and precancerous cervical lesions,

colorectal cancer and skin conditions.  Our aim is to provide solutions that can

improve health outcomes for patients worldwide.  Photocure is listed on the

stock exchange (OSE: PHO).  Information about Photocure is available at

www.photocure.com

About Hexvix®/Cysview®(USA name)

Hexvix®/Cysview® (hexaminolevulinate hydro-chloride) is an innovative

breakthrough technology in the diagnosis and management of non-muscle-invasive

bladder cancer. It is designed to selectively target malignant cells in the

bladder and induce fluorescence during a cystoscopic procedure using a blue

light enabled cystoscope. Using Hexvix®/Cysview® as an adjunct to standard white

light cystoscopy enables the urologist to better detect and remove lesions,

leading to a reduced risk of recurrence. Hexvix®/Cysview® is approved in Europe,

USA and Canada.

About bladder cancer

Bladder cancer is the fifth most common cancer in men with more than 330 000 new

cases annually and more than 130 000 die of the disease. It has a high

recurrence rate with an average of 61% in one year and 78% over five years,

making the lifetime costs of managing bladder cancer one of the highest amongst

all cancers. It is a costly, potentially progressive disease for which patients

have to undergo multiple surveillance cystoscopies because of the high risk of

recurrence. A recent paper on the economic burden of bladder cancer across the

European Union estimates that bladder cancer cost the EU 4,9 billion Euro in

2012.There is an urgent need to improve both the diagnosis and the management of

bladder cancer for the benefit of patients and healthcare systems alike.

This information is subject of the disclosure requirements acc. to §5-12 vphl

(Norwegian Securities Trading Act)

[HUG#1993923]